Influenza Virus Vaccine, Live Dosage

Medically reviewed by Drugs.com. Last updated on Sep 30, 2024.

Usual Adult Dose for Influenza Prophylaxis

PATIENTS UP TO 49 YEARS: 0.2 mL intranasally once

Comments:

• The dose should be administered as a 0.1 mL dose per nostril.
• Active inhalation (sniffing) is not needed during administration.

Use: Active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine

Usual Pediatric Dose for Influenza Prophylaxis

PATIENTS 2 TO 8 YEARS: 0.2 mL intranasally once OR in two-0.2 mL separate doses

PATIENTS 9 YEARS AND OLDER: 0.2 mL intranasally once

Comments:

• The dose should be administered as a 0.1 mL dose per nostril.
• If administering 2 doses, doses should be given at least 1 month apart.
• The Advisory Committee on Immunization Practices (ACIP) should be consulted regarding annual recommendations to determine the number of doses.
• Active inhalation (sniffing) is not needed during administration.

Use: Active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Severe allergic reaction (e.g., anaphylaxis) to the active component or any of the ingredients, including egg protein
• Severe allergic reaction after a previous dose of any influenza vaccine
• Concomitant aspirin or aspirin-containing therapy in children and adolescents

Safety and efficacy have not been established in patients younger than 2 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Do not inject.
• The manufacturer product information should be consulted.

Storage requirements:

• Refrigerate; do not freeze.
• Keep in carton to protect from light.
• Each dose must contain 0.2 mL of vaccine.

Reconstitution/preparation techniques:

• The manufacturer product information should be consulted.

Patient advice:

• To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS): https://vaers.hhs.gov
• Inform patients/caregivers that this is an attenuated live virus vaccine and has the potential for transmission to immunocompromised contacts.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer